28 June 2022

Telin Subsidiaries Conducted Their Annual General Meeting of Shareholders for the Financial Year 2021

Telin holds its subsidiaries' Annual General Meeting of Shareholders (AGMS) in a hybrid mode, discussing achievements in 2021, including significant revenue growth in Telin USA and positive results in Telin Singapore, Hong Kong, and Taiwan.

24 June 2022

Telin NeuTrafiX is Recognized at the 6th Carrier Community Global Awards 2022

Telin receives the Best Voice/Data Service Innovation award at the 6th annual Carrier Community Global Awards for its innovative NeuTrafiX product, revolutionizing the connectivity business and addressing industry challenges.

15 June 2022

Telin Annual General Meeting of Shareholders for the 2021 Financial Year

Telin reports impressive financial results for 2021 with a 9% revenue growth to Rp10.49 trillion, reflecting the company's adaptability to the digital age and strategic partnerships with digital players.

07 June 2022

Telin welcomes Coolwave Communications as member in NeuTrafiX Marketplace

Coolwave Communications, a global voice and messaging solutions provider, joins Telin's NeuTrafiX connectivity marketplace, expanding its inventory and reach for users globally. NeuTrafiX simplifies number trading, offering a collaborative platform for operators, carriers, and enterprises to enhance their services and customer experience.

07 June 2022

Telin Named Rising Star Partner of the Year 2022 by Nexusguard

Telin earns recognition as the "Rising Star Partner of the Year 2022" at the Nexusguard Partner APAC Awards 2022 for its innovative cybersecurity solutions, facilitating global expansion for its clients. Telin's commitment to digital transformation and cybersecurity support is acknowledged in this prestigious award.

16 May 2022

Telin Supports Communities in Multiple Countries

For Ramadan this year, Telin carried out charity activities to help micro, small & medium enterprises (MSMEs), orphanages, and local communities to accelerate their recovery from to COVID-19.